Neurotoxic effects during vidarabine therapy for herpes zoster.
Two cases of neurotoxic effects resulting from therapy with vidarabine are described. Both patients were undergoing treatment for cutaneously disseminated herpes zoster complicating therapy for solid malignant tumours. Both had normal renal function. The serum levels of hepatic enzymes were normal in one patient and slightly elevated in the other. Neurotoxicity was first manifested in both patients by the development of intention tremors that progressed to gross tremors. Obtundation, coma and death ensued in one patient and pain syndromes in the other. Vidarabine-induced neurotoxic effects, which may occur in the absence of hepatic or renal dysfunction or treatment with another drug, may be mild initially but may progress rapidly to more serious, even life-threatening, conditions. Presentation of neurotoxic effects should be considered an indication for withdrawal of vidarabine.
D000368:Aged; D005260:Female; D006323:Heart Arrest / Q000209:etiology; D006562:Herpes Zoster / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D010146:Pain / Q000139:chemically induced; D011015:Pneumonia, Aspiration / Q000150:complications; D014202:Tremor / Q000139:chemically induced; D014740:Vidarabine / Q000009:adverse effects*
D014740:Vidarabine